No abstract

Background: The prevalence of disease subtypes of spinocerebellar degenerations (SCDs) varies between countries, and even between areas within a country. We report unprecedented epidemiologic data on SCDs in the Hokuriku district, which is located in the central, western part of Japan. Methods: Clinical and genetic data on SCD patients were obtained via questionnaires distributed to all the departments of neurology, psychiatry and internal medicine in the Hokuriku district (n = 418). Results: Among the SCD patients, autosomal dominant cerebellar ataxias (ADCAs) were noted in 40.4%, multiple system atrophy in 24.7%, cortical cerebellar atrophy in 13.3% and autosomal recessive cerebellar ataxia in 0.3%. Genetically confirmed ADCA patients included those with Machado-Joseph disease (MJD)/spinocerebellar ataxia type 3 (SCA3; 63.3%), SCA6 (20.0%), ADCA linked to chromosome 16q22.1 (10.0%), dentatorubral pallidoluysian atrophy (4.4%), SCA1 (1.1%) and SCA2 (1.1%). MJD/SCA3 was highly prevalent in the Toyama prefecture of the Hokuriku district, accounting for 90% of genetically confirmed ADCAs by birthplace; MJD/SCA3 patients were concentrated in the Gosei area, the western part of the Toyama prefecture, giving an estimated prevalence of 19.1 per 100,000 inhabitants. Conclusions: The Hokuriku district, especially the Gosei area of Toyama, had a surprisingly high relative frequency and prevalence of MJD/SCA3, which is comparable to that in the Azores, Portugal.

No abstract

Anti-muscle-specific receptor tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) patients show various responses to conventional immunosuppressive treatment and some patients are resistant to these therapies. We report a 50-year-old Japanese man with anti-MuSK antibody-positive MG, who showed no or poor response to various therapies, including plasmapheresis, corticosteroid, and tacrolimus. The patient was then treated with intravenous immunoglobulin (IVIG), and showed a good response that persisted over 20 months. The outcome of this case suggests that IVIG treatment may be an effective therapeutic option for anti-MuSK antibody-positive MG, with a potentially long-term effect.

No abstract